Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin

References

• Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015 Jan 24. 385(9965):362–10. doi:10.1016/S0140-6736(14)60236-1.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yamamoto A, Komiya T, Takeshita N, Takahashi M. Seroprevalence of tetanus toxoid antibody and booster vaccination efficacy in Japanese travelers. J Infect Chemother. 2014 Jan. 20(1):35–7. doi:10.1016/j.jiac.2013.11.003.
   PubMed Web of Science ®Google Scholar
• Lamberto Y, Vargas C, Sanchez Cunto M, Saul P, Chediack V, Cunto E. Tetanus: an immunopreventable disease. Medicina. 2023;83(5):841–5. Tetanos: una enfermedad inmunoprevenible.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Total tetanus: reported cases by WHO region. [accessed 2024 Jan 10].https://apps.who.int/gho/data/view.main.1520_46?lang=en.
   Google Scholar
• Behrens H, Ochmann S, Dadonaite B, Roser M. Tetanus. 2019. [accessed 2024 Jan 5]. https://ourworldindata.org/tetanus
   Google Scholar
• Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF. Changes in anti-tetanus antibodies under sero-toxoid therapy. Study in 50 patients with tetanus. Nouv Presse Med. 1976 27;5(13):847–50. Evolution sours sero-anatoxinotherapie des anticorps anti-tetaniques. Etude chez 50 tetaniques.
   PubMedGoogle Scholar
• Gibson RB, Banzhaf EJ. The quantitative changes in the proteins in the blood plasma of horses in the course of immunization. J Exp Med. 1910 May 1;12(3):411–34. doi:10.1084/jem.12.3.411.
   PubMedGoogle Scholar
• Wang H, Yu R, Fang T, Yu T, Chi X, Zhang X, Liu S, Fu L, Yu C, Chen W. Tetanus neurotoxin neutralizing antibodies screened from a human immune scfv antibody phage display library. Toxins. 2016 Sep 11;8(9):266. doi:10.3390/toxins8090266.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons SP, Clark KC, Wilkerson R, Shapiro MA. Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes. Vaccine. 2000 Aug 15;19(1):114–21. doi:10.1016/s0264-410x(00)00115-8.
   PubMed Web of Science ®Google Scholar
• Scott N, Qazi O, Wright MJ, Fairweather NF, Deonarain MP. Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding. Mol Immunol. 2010 Jun;47(10):1931–41. doi:10.1016/j.molimm.2010.02.020.
   PubMed Web of Science ®Google Scholar
• de Smit H, Ackerschott B, Tierney R, Stickings P, Harmsen MM. A novel single-domain antibody multimer that potently neutralizes tetanus neurotoxin. Vaccine: X. 2021 Aug;8:100099. doi:10.1016/j.jvacx.2021.100099.
   PubMedGoogle Scholar
• Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. Neutralization of tetanus toxin by a novel chimeric monoclonal antibody. Toxicon: Official J Int Soc Toxinol. 2021 Oct 15;201:27–36. doi:10.1016/j.toxicon.2021.08.011.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen Y, Cui J, Liu D, Zhang W, Xue C, Xiong X, Liu G, Chen H. Preparation and characterization of a neutralizing murine monoclonal antibody against tetanus toxin. J Immunol Methods. 2023 Feb;513:113427. doi:10.1016/j.jim.2023.113427.
   PubMed Web of Science ®Google Scholar
• Nejad HR, Mehrabadi JF, Saeedi P, Zanganeh S. Phage display technology for fabricating a recombinant monoclonal ScFv antibody against tetanus toxin. Toxicol Res (Camb). 2023 Aug;12(4):591–8. doi:10.1093/toxres/tfad050.
   PubMedGoogle Scholar
• Yousefi M, Younesi V, Bayat AA, Jadidi-Niaragh F, Abbasi E, Razavi A, Khosravi-Eghbal R, Asgarian-Omran H, Shokri F. Comparative human and mouse antibody responses against tetanus toxin at clonal level. J Immunotoxicol. 2016;13(2):243–8. doi:10.3109/1547691X.2015.1046572.
   PubMed Web of Science ®Google Scholar
• Konning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, Schröter C, Sellmann C, Hock B, Kolmar H, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017 Aug;45:10–16. doi:10.1016/j.sbi.2016.10.019.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775–97. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016 Jul;21(7):1076–113. doi:10.1016/j.drudis.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Fu Y, da Fonseca Rezende EMJ, Fleming BD, Renn A, Chen CZ, Hu X, Xu M, Gorshkov K, Hanson Q, Zheng W, et al. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. PLOS ONE. 2022;17(8):e0272364. doi:10.1371/journal.pone.0272364.
   PubMed Web of Science ®Google Scholar
• Ye G, Gallant JP, Massey C, Shi K, Tai W, Zheng J, Odle AE, Vickers MA, Shang J, Wan Y, et al. The development of a novel nanobody therapeutic for SARS-CoV-2. bioRxiv : Preprint Server Biol. 2020 Nov 17. doi:10.1101/2020.11.17.386532.
   Google Scholar
• Yu R, Wang S, Yu YZ, Du W-S, Yang F, Yu W-Y, Sun Z-W. Neutralizing antibodies of botulinum neurotoxin serotype a screened from a fully synthetic human antibody phage display library. J Biomol Screen. 2009 Sep;14(8):991–8. doi:10.1177/1087057109343206.
   PubMedGoogle Scholar
• Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002 Nov;27(11):552–8. doi:10.1016/s0968-0004(02)02177-1.
   PubMed Web of Science ®Google Scholar
• Anderson R, Gao XM, Papakonstantinopoulou A, Roberts M, Dougan G. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect Immun. 1996 Aug;64(8):3168–73. doi:10.1128/iai.64.8.3168-3173.1996.
   PubMed Web of Science ®Google Scholar
• Fairweather NF, Chatfield SN, Makoff AJ, Strugnell RA, Bester J, Maskell DJ, Dougan G. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect Immun. 1990 May;58(5):1323–6. doi:10.1128/iai.58.5.1323-1326.1990.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Nixon P, Kuroda H, Svab Z, Clare S, Bowe F, Fairweather N, Ytterberg J, Wijk, KJ, Dougan G, et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 2003;31(4):1174–9. doi:10.1093/nar/gkg221. 15.
   PubMed Web of Science ®Google Scholar
• Liu FJ, Shi DY, Li ZY, Lu J-S, Wang R, Pang X-B, Yang Z-X, Yu Y-Z. Evaluation of a recombinant tetanus toxin subunit vaccine. Toxicon: Official J Int Soc Toxinol. 2020 Nov;187:75–81. doi:10.1016/j.toxicon.2020.08.001.
   PubMed Web of Science ®Google Scholar
• Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009 Aug;198(3):157–74. doi:10.1007/s00430-009-0116-7.
   PubMed Web of Science ®Google Scholar
• Godakova SA, Noskov AN, Vinogradova ID, Ugriumova, GA, Solovyev, AI, Esmagambetov, IB, Tukhvatulin, AI, Logunov, DY, Naroditsky, BS, Shcheblyakov, DV, et al. Camelid VHHs fused to human fc fragments provide long term protection against botulinum neurotoxin a in mice. Toxins. 2019 Aug 7;11(8):464. doi:10.3390/toxins11080464.
   PubMed Web of Science ®Google Scholar
• Rossetto O, Montecucco C. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins. 2019 Nov 22;11(12):686. doi:10.3390/toxins11120686.
   PubMed Web of Science ®Google Scholar
• Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. Epitope mapping of tetanus toxin by monoclonal antibodies: implication for immunotherapy and vaccine design. Neurotox Res. 2020 Feb;37(2):239–49. doi:10.1007/s12640-019-00096-w.
   PubMed Web of Science ®Google Scholar
• Chen C, Fu Z, Kim JJ, Barbieri JT, Baldwin MR. Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem. 2009 Sep 25;284(39):26569–77. doi:10.1074/jbc.M109.027391.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Papini E, Genna G, Montecucco C. An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun. 1990 Dec;58(12):4136–41. doi:10.1128/iai.58.12.4136-4141.1990.
   PubMed Web of Science ®Google Scholar
• Restani L, Novelli E, Bottari D, Leone P, Barone I, Galli‐Resta L, Strettoi E, Caleo M. Botulinum neurotoxin a impairs neurotransmission following retrograde transynaptic transport. Traffic. 2012 Aug; 13(8):1083–9. doi:10.1111/j.1600-0854.2012.01369.x.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Azarnia Tehran D, Zanetti G, Megighian A, Scorzeto M, Fillo S, Shone C, Binz T, Rossetto O, Lista F, et al. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 2014 Sep 25;8(6):1870–8. doi:10.1016/j.celrep.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Azarnia Tehran D, Zanetti G, Lista F, Binz T, Shone CC, Rossetto O, Montecucco C. The thioredoxin reductase–Thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles. Toxicon: Official J Int Soc Toxinol. 2015 Dec 1;107(Pt A):32–6. doi:10.1016/j.toxicon.2015.06.019.
   PubMedGoogle Scholar
• Pirazzini M, Azarnia Tehran D, Leka O, Zanetti G, Rossetto O, Montecucco C. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta (BBA) - Biomembranes. 2016 Mar;1858(3):467–74. doi:10.1016/j.bbamem.2015.08.014.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu C, Yu J, Lin S, Liu T, Zan L, Li N, Hong P, Wang X, Jia Z. et al. Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. Cell Rep. 2021 May 4;35(5):109070. doi:10.1016/j.celrep.2021.109070.
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Seifi-Najmi M, Ghasemi B, Kafil HS, Alinejad V, Sadreddini S, Younesi V, Jadidi-Niaragh F, Yousefi M. Design and construction of immune phage antibody library against Tetanus neurotoxin: production of single chain antibody fragments. Hum Antibodies. 2015 Dec 23;23(3–4):73–9. doi:10.3233/HAB-150287.
   PubMedGoogle Scholar
• Arunachalam B, Ghosh S, Talwar GP, Raghupathy R. A single human monoclonal antibody that confers total protection from tetanus. Hybridoma. 1992 Apr;11(2):165–79. doi:10.1089/hyb.1992.11.165.
   PubMedGoogle Scholar
• Chin J, Sohn Y, Lee SH, Park YI, Choi MJ. Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell. Biol: J Int Assoc Biol Standardization. 2003 Mar;31(1):45–53. doi:10.1016/s1045-1056(02)00092-1.
   Google Scholar
• Minamitani T, Kiyose K, Otsubo R, Ito T, Akiba H, Furuta RA, Inoue T, Tsumoto K, Satake M, Yasui T, et al. Novel neutralizing human monoclonal antibodies against tetanus neurotoxin. Sci Rep. 2021 June 9;11(1):12134. doi:10.1038/s41598-021-91597-2.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Grinzato A, Corti D, Barbieri S, Leka O, Vallese F, Tonellato M, Silacci-Fregni C, Piccoli L, Kandiah E, et al. Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. J Clin Invest. 2021 Nov 15;131(22). doi:10.1172/JCI151676.
   PubMed Web of Science ®Google Scholar
• Rossotti MA, Gonzalez-Techera A, Guarnaschelli J, Yim L, Camacho X, Fernández M, Cabral P, Leizagoyen C, Chabalgoity JA, González-Sapienza G. et al. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain. Mabs-austin. 2015;7(5):820–8. doi:10.1080/19420862.2015.1068491.
   PubMed Web of Science ®Google Scholar
• Aliprandini E, Takata DY, Lepique A, Kalil J, Boscardin SB, Moro AM. An oligoclonal combination of human monoclonal antibodies able to neutralize tetanus toxin in vivo. Toxicon: X. 2019 Apr;2:100006. doi:10.1016/j.toxcx.2019.100006.
   PubMedGoogle Scholar